Skip to main content

Table 2 Number of events, time on dialysisa, 1- and 2-year cumulative incidence, and adjusted subdistribution hazard ratios of kidney transplantation and death before KT, by donor group

From: Practice patterns of dialysis access and outcomes in patients wait-listed early for kidney transplantation

Outcome

Awaiting deceased-donor KT

Awaiting living-donor KT

Hemodialysis with AV access (n = 4752)

Hemodialysis with catheter

(n = 1956)

Peritoneal

dialysis

(n = 1634)

Hemodialysis with AV access

(n = 467)

Hemodialysis with catheter

(n = 316)

Peritoneal dialysis

(n = 206)

Kidney transplantation

 Number of events

3172

1157

1148

262

205

119

 Median time on dialysisa (IQR), months

14.8 (7.4–26.5)

15.9 (8.3–27.6)

13.6 (7.0–25.1)

8.9 (5.6–17.3)

7.5 (4.3–12.0)

9.7 (5.1–16.4)

 1-year cumulative incidence (IQR), %

10 (9–10)

4 (3–4)

14 (13–16)

26 (23–30)

27 (24–30)

30 (25–36)

 Adjustedb SHR (95% CI)

Reference

0.88 (0.82–0.94)

1.01 (0.94–1.09)

Reference

1.18 (0.95–1.45)

0.93 (0.72–1.19)

Death before KT

 Number of events

149

107

44

0

3

2

 Median time on dialysisa (IQR), months

26.9 (11.1–41.7)

19.2 (7.6–36.5)

22.2 (15.8–37.8)

20.2 (16.5–26.1)

7.1 (7.1–13.4)

 1-year cumulative incidence (IQR), %

5 (5–5)

14 (13–14)

6 (5–7)

0

0.4 (0.04–1.9)

 Adjustedc SHR (95% CI)

Reference

1.53 (1.14–2.04)d

1.12 (0.80–1.56)d

  1. aIn patients who had the event
  2. bSubdistribution hazard ratios of kidney transplantation were adjusted for gender, age, region (as strata), year of dialysis initiation, history of diabetes, peripheral arterial disease, serum albumin, panel reactive antibody level, blood group, temporary inactive status, and ownership of the nephrology facility
  3. cSubdistribution hazard ratios of death before kidney transplantation included a time interaction term for dialysis modality and were adjusted for gender, age, region (as strata), history of diabetes, peripheral arterial disease, previous transplantation (kidney excluded), number of cardiovascular comorbidities (as strata), mobility status, and serum albumin. These were not estimated for the group awaiting living-donor kidney transplant because of the small number of events
  4. dHazard ratio at 12 months of follow-up